ENSAYOS CLÍNICOS MELANOMA, TUMORES CUTÁNEOS, SNC, PULMÓN, SARCOMA Y CABEZA CUELLO.

- MELANOMA

GEM-1802

“MULTICENTRE PHASE II CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ENCORAFENIB AND BINIMETINIB BEFORE LOCAL TREATMENT IN PATIENTS WITH BRAF MUTATED MELANOMA WITH METASTASIS TO THE BRAIN.”

https://clinicaltrials.gov/ct2/show/NCT03898908?term=GEM-1802&draw=2&rank=1

BNT111-01

“Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma”


REGENERON (R2810-ONC-1788)

“A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA”


20-214-29 / CA045-022 (PIVOT-12)

“A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)”


C4221016 (STARBOARD) CERRADA FASE SLI, PENDIENTE APERTURA FASE 3

“A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma”

https://www.clinicaltrials.gov/ct2/show/NCT04657991?term=C4221016&cond=MELANOMA&draw=2&rank=1
- CABEZA Y CUELLO

INTERLINK-1

“Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)”

https://clinicaltrials.gov/ct2/show/NCT04590963?term=INTERLINK+1&draw=2&rank=1

AN2025H0301 (BURAN)

“The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma”

https://www.clinicaltrials.gov/ct2/show/NCT04338399?term=AN2025H0301&cond=Head+and+Neck+Cancer&draw=2&rank=1

- TIROIDES

J2G-MC-JZJB (LIBRETTO-531)

“A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer”


- PULMÓN

TAK300X3-A300X3/ BRIGATINIB 3001

“An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive (ALK+) Non-Small-Cell Lung Cancer (NSCLC) Participants Who Have Progressed on Crizotinib (ALTA-3)”

https://clinicaltrials.gov/ct2/show/NCT03596866?term=BRIGATINIB+3001&draw=2&rank=1

BO29554 (B-FAST)

“A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON–SMALL CELL LUNG CANCER (NSCLC) HARBOURING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL)”

https://clinicaltrials.gov/ct2/show/NCT03178552?term=BO29554&rank=1

CA209-73L
“A Phase 3, Randomized, Open Label Study to Compare Nivolumab plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC)”


**TAK 788-3001 (EXCLAIM-2)**

“A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutation”


**GO41854 (SKYSCRAPER 03)**

“A Phase III, Open-label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation”


**BO42864 (AcceleRET-Lung)**

“A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer”


**CINC280A2301**

“A phase III, randomized, controlled, open-label, multicenter, global study of capmatinib versus SoC docetaxel chemotherapy in previously treated patients with EGFR wt, ALK negative, locally advanced or metastatic (stage IIIb/IIIC or IV) NSCLC harboring MET exon 14 skipping mutation”


**MARIPOSA (73841937NSC3003)**

“A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer”

https://clinicaltrials.gov/ct2/show/NCT04487080?term=MARIPOSA&draw=2&rank=1

**PAPILLON (61186372NSC3001)**
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions


ZEAL (213400)
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy


APL-101-01 (SPARTA)
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors


MK-7684A-002
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002)


Amgen 20170543 (CodeBreak 100)
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)


CINC280L12301
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

https://www.clinicaltrials.gov/ct2/show/NCT04816214?term=CINC280L12301&draw=2&rank=1

EORTC-1825-LCG (ALKALINE)
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

https://www.clinicaltrials.gov/ct2/show/NCT04127110?term=ALKALINE&cond=Lung+Cancer&draw=2&rank=1

D6185C00001 (HUDSON)
This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.

https://clinicaltrials.gov/ct2/show/NCT03334617?term=HUDSON&draw=2&rank=1

- SARCOMAS

GEIS 40

“Phase II, single arm, non-randomized and multicenter clinical trial of regorafenib as a single agent in the first-line setting for patients with metastatic and/or unresectable KIT/PDGFR Wild Type GIST”

https://clinicaltrials.gov/ct2/show/NCT02638766?term=REGISTRI&rank=1

GEIS 42

“Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III study”

https://clinicaltrials.gov/ct2/show/NCT02413736?term=SSGXXII&rank=1

GEIS-75 (Synergias)

“Multicohort Trial of Trabectedin and Low-dose Radiation Therapy in Advanced/Metastatic Sarcomas”

https://www.clinicaltrials.gov/ct2/show/NCT05131386?term=geis-75&draw=2&rank=1

GEIS-35 (rEECur)

“International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma”

No link available

FaR-RMS

Treatment of Recurrent and Primary Refractory Ewing Sarcoma” FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

https://clinicaltrials.gov/ct2/show/NCT04625907?term=faR-RMS&draw=2&rank=1

RAIN-3201 (MANTRA)
Randomized, multicenter, open-label, Phase 3 registration study designed to evaluate the safety and efficacy of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy.

https://clinicaltrials.gov/ct2/show/NCT04979442?term=RAIN-3201&draw=2&rank=1